TP53 and cancer: Similar to most cancers, CLL is a heterogeneous disease with various known genetic alterations, such as 17p deletion (del[17p]), tumor protein 53 (TP53) mutation, and 11q deletion (del[11q]), which have been identified as unfavorable prognostic markers in patients treated with chemoimmunotherapy2,3.